You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CARDIZEM SR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Cardizem Sr, and when can generic versions of Cardizem Sr launch?

Cardizem Sr is a drug marketed by Biovail and is included in one NDA.

The generic ingredient in CARDIZEM SR is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cardizem Sr

A generic version of CARDIZEM SR was approved as diltiazem hydrochloride by TEVA on May 31st, 1995.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CARDIZEM SR?
  • What are the global sales for CARDIZEM SR?
  • What is Average Wholesale Price for CARDIZEM SR?
Summary for CARDIZEM SR
Drug patent expirations by year for CARDIZEM SR
Recent Clinical Trials for CARDIZEM SR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assiut UniversityEarly Phase 1
CAMC Health SystemPhase 4
University of South FloridaN/A

See all CARDIZEM SR clinical trials

US Patents and Regulatory Information for CARDIZEM SR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biovail CARDIZEM SR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019471-001 Jan 23, 1989 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Biovail CARDIZEM SR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019471-004 Jan 23, 1989 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Biovail CARDIZEM SR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019471-002 Jan 23, 1989 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Biovail CARDIZEM SR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019471-003 Jan 23, 1989 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CARDIZEM SR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Biovail CARDIZEM SR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019471-004 Jan 23, 1989 ⤷  Sign Up ⤷  Sign Up
Biovail CARDIZEM SR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019471-001 Jan 23, 1989 ⤷  Sign Up ⤷  Sign Up
Biovail CARDIZEM SR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019471-003 Jan 23, 1989 ⤷  Sign Up ⤷  Sign Up
Biovail CARDIZEM SR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019471-002 Jan 23, 1989 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CARDIZEM SR

See the table below for patents covering CARDIZEM SR around the world.

Country Patent Number Title Estimated Expiration
Portugal 88776 PROCESSO PARA A PREPARACAO DE FORMULACOES DE DILTIAZEM DE ABSORCAO CONTROLADA ⤷  Sign Up
Ireland 60929 Controlled absorption diltiazem formulation ⤷  Sign Up
Germany 3485023 ⤷  Sign Up
Japan H01132521 DILTIAZEM PREPARATION OF CONTROLLED ABSORPTION ⤷  Sign Up
Japan S60156617 PHAMACEUTICAL BLEND ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.